We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lipid Cutoffs Identified for CVD Risk in Young Adults Without Diabetes

By LabMedica International staff writers
Posted on 09 Aug 2022

The underlying pathogenesis and progression associated with nearly all cardiovascular diseases (CVDs) are predominantly of atherosclerotic origin that leads to the development of coronary artery disease, cerebrovascular disease, venous thromboembolism and, peripheral vascular disease, subsequently causing myocardial infarction (MI), cardiac arrhythmias or stroke. More...

The etiological risk factors leading to the onset of CVDs are well recognized and include hyperlipidemia, hypertension, diabetes, obesity, smoking and, lack of physical activity. They collectively represent more than 90% of the CVD risks in all epidemiological studies. Despite high fatality rate of CVDs, the identification and careful prevention of the underlying risk factors can significantly reduce the global epidemic of CVDs.

Endocrinologists at the Yeouido St. Mary’s Hospital (Seoul, South Korea) used data from the nationally representative Korean National Health Insurance System database to identify lipid cutoffs associated with increased risk for CVD among adults aged 20 to 39 years without diabetes. The analysis consisted of 6,204,153 young adults who underwent health examinations from 2009 to 2012 and followed until the end of 2018. The primary outcome was incident CVD, defined as MI and stroke. 

The investigators reported that during a median follow-up of 7.7 years, there were 14,569 (0.23%) cases of myocardial infarction, 9,459 (0.15%) cases of stroke, and 23,680 (0.38%) cases of composite CVD. Using total cholesterol (TC) level of <140 mg/dL, triglyceride (TG) level of <60 mg/dL, LDL-cholesterol level of <100 mg/dL, and non-HDL-cholesterol level of <130 mg/dL as reference groups, a significantly higher risk of CVD was observed in subjects with a TC level of ≥200 mg/dL, TG level of ≥60 mg/dL, LDL-cholesterol level of ≥130 mg/dL, or non-HDL-cholesterol level of ≥140 mg/dL. The cutoff levels of TC that had statistical significance for increased risk of CVD were 240, 220, and 200 mg/dL in subjects with 0, 1, or 2–3 risk factors, respectively.

Mee Kyoung Kim, MD, PhD, the senior author of the study, said, “Considerable uncertainty exists about the extent to which slightly increased cholesterol levels affect long-term cardiovascular risk and about which cutoff should be used to merit a treatment recommendation in young people. Our study extends the current knowledge because it suggests that even slightly increased concentrations of total cholesterol, LDL-C, non-HDL-C and triglycerides may predict long-term cardiovascular risk in young populations.”

The authors concluded that at present, calculated risk is one of the primary criteria adopted by guidelines to initiate lipid-lowering therapy to reduce the subsequent risk of CVD. Because age is the principal determinant used in risk engines or guideline algorithms, lipid-lowering interventions become common only after 60 years of age except for those with markedly elevated LDL-C levels or diabetes. Although the 10-year risk is low in young and middle-aged adults who are not treated according to current guidelines, they ultimately account for most incident of Atherosclerotic Cardiovascular Disease (ASCVD) cases.” The final version of the study was published on July 27, 2022 in the journal European Journal of Preventive Cardiology.

Related Links:
Yeouido St. Mary’s Hospital


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.